Advertisement
American Journal of Kidney Diseases

Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function

Published:September 28, 2022DOI:https://doi.org/10.1053/j.ajkd.2022.07.014

      Rationale & Objective

      Anemia is common in chronic kidney disease (CKD); although anemia is associated with adverse outcomes, the available treatments are not ideal. We characterized the burden, risk factors for, and risks associated with anemia by estimated glomerular filtration rate (eGFR) and hemoglobin level.

      Study Design

      Cross-sectional and prospective cohort study.

      Setting & Participants

      Outpatient data from 5,004,957 individuals across 57 health care centers in the United States from 2016 to 2019, extracted from the Optum Labs Data Warehouse.

      Exposure

      Severity of anemia, presence of low iron test results, eGFR.

      Outcome

      Incident kidney failure with replacement therapy, cardiovascular disease, coronary heart disease, stroke, heart failure, death.

      Analytical Approach

      The prevalences of anemia, low iron test results, vitamin B12 deficiency, and erythropoiesis-stimulating agent (ESA) use, stratified by sex and eGFR, were characterized. Polychotomous logistic regression was used to estimate the adjusted odds ratios of different hemoglobin levels across eGFR. Cox proportional hazards regression was used to calculate adjusted hazard ratios for adverse outcomes across hemoglobin level.

      Results

      The mean age was 54 years, and 42% were male. Lower eGFR was very strongly associated with increased prevalence of anemia, even after adjustment. Although iron studies were checked infrequently in patients with anemia, low iron test results were highly prevalent in those tested: 60.4% and 81.3% of men and women, respectively. ESA use was uncommon, with a prevalence of use of <4%. Lower hemoglobin was independently associated with increased risk of incident kidney failure with replacement therapy, cardiovascular disease, coronary heart disease, stroke, heart failure, and death.

      Limitations

      Reliance on ICD codes for medical diagnoses, death information obtained from claims data, observational study.

      Conclusions

      Severe anemia was common and strongly associated with lower eGFR and multiple adverse outcomes. Low-iron test results were highly prevalent in those tested despite iron studies being checked infrequently. ESA use in nondialysis CKD patients was uncommon.

      Graphical abstract

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. World Health Organization. Nutritional Anaemias: Report of a WHO Scientific Group. World Health Organization; 1968.

        • Astor B.C.
        • Muntner P.
        • Levin A.
        • et al.
        Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994).
        Arch Intern Med. 2002; 162: 1401-1408https://doi.org/10.1001/archinte.162.12.1401
        • Hsu C.Y.
        • McCulloch C.E.
        • Curhan G.C.
        Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey.
        J Am Soc Nephrol. 2002; 13: 504-510https://doi.org/10.1681/ASN.V132504
        • Inker L.A.
        • Grams M.E.
        • Levey A.S.
        • et al.
        • CKD Prognosis Consortium
        Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a global consortium.
        Am J Kidney Dis. 2019; 73: 206-217https://doi.org/10.1053/j.ajkd.2018.08.013
        • Stauffer M.E.
        • Fan T.
        Prevalence of anemia in chronic kidney disease in the United States.
        PLoS One. 2014; 9e84943https://doi.org/10.1371/journal.pone.0084943
        • Babitt J.L.
        • Lin H.Y.
        Mechanisms of anemia in CKD.
        J Am Soc Nephrol. 2012; 23: 1631-1634https://doi.org/10.1681/ASN.2011111078
        • Musio F.
        Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary.
        Expert Rev Hematol. 2020; 13: 1175-1188https://doi.org/10.1080/17474086.2020.1830371
        • Astor B.C.
        • Coresh J.
        • Heiss G.
        • et al.
        Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study.
        Am Heart J. 2006; 151: 492-500https://doi.org/10.1016/j.ahj.2005.03.055
        • Hoshino J.
        • Muenz D.
        • Zee J.
        • et al.
        CKDopps Investigators. Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3-5 nondialysis CKD.
        J Ren Nutr. 2020; 30: 404-414https://doi.org/10.1053/j.jrn.2019.11.003
        • Sarnak M.J.
        • Tighiouart H.
        • Manjunath G.
        • et al.
        Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) Study.
        J Am Coll Cardiol. 2002; 40: 27-33https://doi.org/10.1016/s0735-1097(02)01938-1
        • Weiner D.E.
        • Tighiouart H.
        • Vlagopoulos P.T.
        • et al.
        Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease.
        J Am Soc Nephrol. 2005; 16: 1803-1810https://doi.org/10.1681/ASN.2004070597
        • Drüeke T.B.
        • Locatelli F.
        • Clyne N.
        • et al.
        CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
        N Engl J Med. 2006; 355: 2071-2084https://doi.org/10.1056/NEJMoa062276
        • Hayashi T.
        • Maruyama S.
        • Nangaku M.
        • et al.
        PREDICT Investigators. Darbepoetin alfa in patients with advanced CKD without diabetes: randomized, controlled trial.
        Clin J Am Soc Nephrol. 2020; 15: 608-615https://doi.org/10.2215/CJN.08900719
        • Jing Z.
        • Wei-jie Y.
        • Nan Z.
        • et al.
        Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis.
        PLoS One. 2012; 7e43655https://doi.org/10.1371/journal.pone.0043655
        • Koulouridis I.
        • Alfayez M.
        • Trikalinos T.A.
        • et al.
        Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
        Am J Kidney Dis. 2013; 61: 44-56https://doi.org/10.1053/j.ajkd.2012.07.014
        • Palmer S.C.
        • Navaneethan S.D.
        • Craig J.C.
        • et al.
        Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
        Ann Intern Med. 2010; 153: 23-33https://doi.org/10.7326/0003-4819-153-1-201007060-00252
        • Pfeffer M.A.
        • Burdmann E.A.
        • Chen C.Y.
        • TREAT Investigators
        • et al.
        A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
        N Engl J Med. 2009; 361: 2019-2032https://doi.org/10.1056/NEJMoa0907845
        • Phrommintikul A.
        • Haas S.J.
        • Elsik M.
        • et al.
        Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.
        Lancet. 2007; 369 (381-288)https://doi.org/10.1016/S0140-6736(07)60194-9
        • Singh A.K.
        • Szczech L.
        • Tang K.L.
        • et al.
        CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease.
        N Engl J Med. 2006; 355: 2085-2098https://doi.org/10.1056/NEJMoa065485
        • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
        KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.
        Kidney Int Suppl. 2013; 3: 1-150
        • Le C.H.
        The prevalence of anemia and moderate-severe anemia in the US population (NHANES 2003-2012).
        PLoS One. 2016; 11e0166635https://doi.org/10.1371/journal.pone.0166635
      2. OptumLabs. OptumLabs and OptumLabs Data Warehouse (OLDW) Descriptions and Citation. OptumLabs, July 2020
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • et al.
        CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612https://doi.org/10.7326/0003-4819-150-9-200905050-00006
        • Antony A.C.
        Megaloblastic anemias.
        in: Hoffman R. Benz E.J. Shattil S.J. Hematology: Basic Principles and Practice. 4th ed. Churchill Livingstone, 2005: 519-556
        • Fernández-Rodríguez A.M.
        • Guindeo-Casasús M.C.
        • Molero-Labarta T.
        • et al.
        Diagnosis of iron deficiency in chronic renal failure.
        Am J Kidney Dis. 1999; 34: 508-513https://doi.org/10.1016/s0272-6386(99)70079-x
        • Kalantar-Zadeh K.
        • Höffken B.
        • Wünsch H.
        • et al.
        Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era.
        Am J Kidney Dis. 1995; 26: 292-299https://doi.org/10.1016/0272-6386(95)90649-5
        • Stancu S.
        • Stanciu A.
        • Zugravu A.
        • et al.
        Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD [published correction appears in Am J Kidney Dis. 2010;5(11):2137-2138].
        Am J Kidney Dis. 2010; 55: 639-647https://doi.org/10.1053/j.ajkd.2009.10.043
        • Thomas D.W.
        • Hinchliffe R.F.
        • Briggs C.
        • et al.
        British Committee for Standards in Haematology. Guideline for the laboratory diagnosis of functional iron deficiency.
        Br J Haematol. 2013; 161: 639-648https://doi.org/10.1111/bjh.12311
        • Tran T.N.
        • Eubanks S.K.
        • Schaffer K.J.
        • Zhou C.Y.
        • Linder M.C.
        Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron.
        Blood. 1997; 90: 4979-4986https://doi.org/10.1182/blood.V90.12.4979
        • Short M.W.
        • Domagalski J.E.
        Iron deficiency anemia: evaluation and management.
        Am Fam Physician. 2013; 87: 98-104
      3. Maner BS, Moosavi L. Mean corpuscular volume. StatPearls, updated July 10, 2021. https://www.ncbi.nlm.nih.gov/books/NBK545275/

        • Astor B.C.
        • Arnett D.K.
        • Brown A.
        • et al.
        Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) Study.
        Am J Kidney Dis. 2004; 43: 836-845https://doi.org/10.1053/j.ajkd.2003.12.047
        • Chang J.M.
        • Chen S.C.
        • Huang J.C.
        • et al.
        Anemia and left ventricular hypertrophy with renal function decline and cardiovascular events in chronic kidney disease.
        Am J Med Sci. 2014; 347: 183-189https://doi.org/10.1097/MAJ.0b013e31827981be
        • Go A.S.
        • Yang J.
        • Tan T.C.
        • et al.
        • Kaiser Permanente Northern California CKD Outcomes Study
        Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus.
        BMC Nephrol. 2018; 19: 146https://doi.org/10.1186/s12882-018-0942-1
        • Mohanram A.
        • Zhang Z.
        • Shahinfar S.
        • et al.
        Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
        Kidney Int. 2004; 66: 1131-1138https://doi.org/10.1111/j.1523-1755.2004.00863.x
        • Yi S.W.
        • Moon S.J.
        • Yi J.J.
        Low-normal hemoglobin levels and anemia are associated with increased risk of end-stage renal disease in general populations: a prospective cohort study.
        PLoS One. 2019; 14e0215920https://doi.org/10.1371/journal.pone.0215920
        • Furuland H.
        • Linde T.
        • Ahlmén J.
        • Christensson A.
        • Strömbom U.
        • Danielson B.G.
        A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.
        Nephrol Dial Transplant. 2003; 18: 353-361https://doi.org/10.1093/ndt/18.2.353
        • Rossert J.
        • Levin A.
        • Roger S.D.
        • et al.
        Effect of early correction of anemia on the progression of CKD.
        Am J Kidney Dis. 2006; 47: 738-750https://doi.org/10.1053/j.ajkd.2006.02.170
        • Awan A.A.
        • Walther C.P.
        • Richardson P.A.
        • et al.
        Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease.
        Nephrol Dial Transplant. 2021; 36: 129-136https://doi.org/10.1093/ndt/gfz192
        • Fishbane S.
        Anemia management: a historical perspective.
        Kidney Int Suppl. 2021; 11: 3-7https://doi.org/10.1016/j.kisu.2020.12.004
        • Raichoudhury R.
        • Spinowitz B.S.
        Treatment of anemia in difficult-to-manage patients with chronic kidney disease.
        Kidney Int Suppl. 2021; 11: 26-34https://doi.org/10.1016/j.kisu.2020.12.006